For the Inventor, By the Inventor

Enter assignee name

London, United Kingdom

Cyclacel Limited

USPTO Granted Patents = 56

CIPO Patents = 5

EPO Patents = 21

Trademarks = 5

Forward Citations = 519

Loading Chart...

Loading Chart...

83 inventors (with patents filed for the assignee):

Peter Martin Fischer (18 out of 20 patents)

Shudong Wang (11 out of 13 patents)

John Colyer (9 out of 12 patents)

4. Simon Richard Green (8 out of 15 patents)

5. Roger Kingdon Craig (7 out of 26 patents)

6. Gavin Wood (6 out of 7 patents)

7. Judy H Chiao (5 out of 11 patents)

8. Robert Westwood (4 out of 17 patents)

9. Stuart Donald Jones (4 out of 4 patents)

10. Ian Fleming (4 out of 4 patents)

11. Stuart Wilson (4 out of 4 patents)

12. Paul Workman (4 out of 8 patents)

13. Daniella I Zheleva (4 out of 4 patents)

14. Christopher Meades (4 out of 5 patents)

15. Edward McDonald (4 out of 22 patents)

Core Competencies:

Purine Derivatives

Pyrimidine Derivatives

Protein Kinase Inhibitors

CDK Inhibitors

Sapacitabine

Decitabine

Antitumor Compounds

Enzymatic Activity Monitoring

Drug Delivery Systems

Cytotoxic Agents

Proliferative Disorders

Peptide Derivatives

56 patents: Sort by Forward Citations

1. 10927113 - Process for preparing purine derivatives (2021-02-23),

2. 10226478 - Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia (2019-03-12),

3. 9872874 - Dosage regimen for sapacitabine and seliciclib (2018-01-23),

4. 9675631 - Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine (2017-06-13),

5. 9573951 - Crystalline forms of a purine derivative (2017-02-21),

6. 9493471 - Pyrimidine derivatives as protein kinase inhibitors (2016-11-15),

7. 9173938 - Combination of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders (2015-11-03),

8. 9133199 - Pyrimidine derivatives as protein kinase inhibitors (2015-09-15),

9. 8975239 - Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine (2015-03-10),

10. 8889861 - Crystalline forms of a purine derivative (2014-11-18),

11. 8884001 - Preparation of intermediates useful in the synthesis of 2'-cyano-2′-deoxy-N4-palmi-toyl-1-β-D-arabinofuranosylcytosine (2014-11-11),

12. 8846696 - Purine derivatives (2014-09-30),

13. 8809350 - Purine and pyrimidine CDK inhibitors and their use for the treatment of autoimmune diseases (2014-08-19),

14. 8592581 - Trisubstituted purine derivatives (2013-11-26),

15. 8563542 - Pyrimidine derivatives as protein kinase inhibitors (2013-10-22),

Cyclacel Limited is a clinical-stage biopharmaceutical company focusing on the development and commercialization of innovative medicines for the treatment of cancer and other diseases. With a commitment to improving patient outcomes, Cyclacel's research and development efforts revolve around targeted therapies that exploit the cell cycle, signaling pathways, and immune system. Through its proprietary drug discovery platforms, Cyclacel aims to provide solutions for unmet medical needs and contribute to the advancement of cancer treatment.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

56 Patents

#60 in London

#304 in United Kingdom

#12,351 in the World

London, United Kingdom

Cyclacel Limited

Forward Citations = 519

83 inventors:

Peter Martin Fischer (18 out of 20 patents)

Shudong Wang (11 out of 13 patents)

John Colyer (9 out of 12 patents)

4. Simon Richard Green (8 out of 15 patents)

5. Roger Kingdon Craig (7 out of 26 patents)

Please report any incorrect information to support@idiyas.com

Loading…